HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01235559

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

Medication studyAges 18+Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Costa Mesa and 89 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateDecember 2010
Recruitment status
Completed
Enrollment listed in the registry
604
Sponsor
Hoffmann-La Roche
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Bulgaria, China, ...
Age range
Over 18 Years
Official registry ID
NCT01235559
Official title
Show the full official title

Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Costa Mesa, United States · Escondido, United States · Granada Hills, United States

78 more locations
  • La Jolla, United States
  • Oceanside, United States
  • San Diego, United States
  • Torrance, United States
  • Lauderhill, United States
  • Orange City, United States
  • Plantation, United States
  • Atlanta, United States
  • Indianapolis, United States
  • Flowood, United States
  • Las Vegas, United States
  • Buffalo, United States
  • New York, United States
  • Rochester, United States
  • Durham, United States
  • Scranton, United States
  • Austin, United States
  • Irving, United States
  • Salt Lake City, United States
  • Burgas, Bulgaria
  • Kazanlak, Bulgaria
  • Novi Iskar, Bulgaria
  • Pazardzhik, Bulgaria
  • Plovdiv, Bulgaria
  • Radnevo, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
  • Baoding, China
  • Beijing, China
  • Changsha, China
  • Chengdu, China
  • GuangzhouGuangdong, China
  • Hangzhou, China
  • Kunming, China
  • Nanjing, China
  • Shanghai, China
  • Wuhan, China
  • Wuxi, China
  • Xi'an, China
  • Brno, Czechia
  • Liberec, Czechia
  • Mělník, Czechia
  • Pilsen, Czechia
  • Prague, Czechia
  • Praha 8 - Bohnice, Czechia
  • Sternberk, Czechia
  • Bari, Italy
  • Naples, Italy
  • Brescia, Italy
  • Milan, Italy
  • Turin, Italy
  • Pisa, Italy
  • Padova, Italy
  • Chiba, Japan
  • Funabashi-shi, Japan
  • Gunma, Japan
  • Hiroshima, Japan
  • Hokkaido, Japan
  • Kanzaki-gun, Japan
  • Kita-ku, Japan
  • Kitakyushu-shi, Japan
  • Kochi, Japan
  • Koshi-shi, Japan
  • Kumamoto, Japan
  • Kurayoshi-shi, Japan
  • Nagoya, Japan
  • Omuta-shi, Japan
  • Sakaishi, Japan
  • Sapporo, Japan
  • Sendai, Japan
  • Shirakawa-shi, Japan
  • Tokyo, Japan
  • Toyama, Japan
  • Toyoake-shi, Japan
  • Yokohama, Japan
  • Saint Petersburg, Russia
  • Czechia
  • Russia
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Hoffmann-La Roche.

Did this study involve medication?

Yes. The study involved medication, including Placebo, bitopertin [RO4917838] level 1 and bitopertin [RO4917838] level 2.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies